Ionis reveals an oasis for HAE patients as RNA med reduces attacks in phase 3

We can now envision the oasis that Ionis Pharmaceuticals saw with its hereditary angioedema data.

Earlier this year, the company announced that donidalorsen had met the primary endpoint of a phase 3 study, but now we know it’s because the treatment spurred an 81% lower monthly rate of swelling attacks in patients who received the drug every four weeks.